Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

Sakura Yamamoto; Jun Wada; Takane Katayama; Takumi Jikimoto; Masakuni Nakamura; Shohiro Kinoshita; Kyung Mi Lee; Masato Kawabata; Toshiro Shirakawa

doi:10.1016/j.vaccine.2010.08.007

Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

Sakura Yamamoto, Jun Wada, Takane Katayama, Takumi Jikimoto, Masakuni Nakamura, Shohiro Kinoshita, Kyung Mi Lee, Masato Kawabata, Toshiro Shirakawa

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×10⁷ CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×10⁷ CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

Original language	English
Pages (from-to)	6684-6691
Number of pages	8
Journal	Vaccine
Volume	28
Issue number	41
DOIs	https://doi.org/10.1016/j.vaccine.2010.08.007
Publication status	Published - 2010 Sept

Keywords

Bifidobacterium
Mucosal vaccine
Salmonella

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2010.08.007

Cite this

@article{9eb6f65f88694a8f8221ea8e85d19cd9,

title = "Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model",

abstract = "We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×107 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×107 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.",

keywords = "Bifidobacterium, Mucosal vaccine, Salmonella",

author = "Sakura Yamamoto and Jun Wada and Takane Katayama and Takumi Jikimoto and Masakuni Nakamura and Shohiro Kinoshita and Lee, {Kyung Mi} and Masato Kawabata and Toshiro Shirakawa",

note = "Funding Information: This study was supported in part by a grant-in-aid for Scientific Research (No. 20591201 ) from Japan Society for the Promotion of Science (JSPS) ; a grant from Hyogo Science and Technology Association ; and a grant-in-aid through the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases , the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. K-M Lee is supported by a grant from KICOS ( K20704000007-09A0500-00710 ).",

year = "2010",

month = sep,

doi = "10.1016/j.vaccine.2010.08.007",

language = "English",

volume = "28",

pages = "6684--6691",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "41",

}

TY - JOUR

T1 - Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

AU - Yamamoto, Sakura

AU - Wada, Jun

AU - Katayama, Takane

AU - Jikimoto, Takumi

AU - Nakamura, Masakuni

AU - Kinoshita, Shohiro

AU - Lee, Kyung Mi

AU - Kawabata, Masato

AU - Shirakawa, Toshiro

N1 - Funding Information: This study was supported in part by a grant-in-aid for Scientific Research (No. 20591201 ) from Japan Society for the Promotion of Science (JSPS) ; a grant from Hyogo Science and Technology Association ; and a grant-in-aid through the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases , the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. K-M Lee is supported by a grant from KICOS ( K20704000007-09A0500-00710 ).

PY - 2010/9

Y1 - 2010/9

N2 - We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×107 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×107 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

AB - We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×107 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×107 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

KW - Bifidobacterium

KW - Mucosal vaccine

KW - Salmonella

UR - http://www.scopus.com/inward/record.url?scp=77956494584&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.08.007

DO - 10.1016/j.vaccine.2010.08.007

M3 - Article

C2 - 20709009

AN - SCOPUS:77956494584

SN - 0264-410X

VL - 28

SP - 6684

EP - 6691

JO - Vaccine

JF - Vaccine

IS - 41

ER -

Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this